Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis

S. Gupta, J. M. Solomon, T. A. Tasciyan, M. M. Cao, R. D. Stone, J. L. Ostuni, J. M. Ohayon, P. A. Muraro, J. A. Frank, N. D. Richert, H. F. McFarland, Francesca Bagnato

Research output: Contribution to journalArticle

Abstract

Interferon-beta (IFNβ) reduces the number and load of new contrast-enhancing lesions (CELs) in patients with multiple sclerosis (MS). However, the ability of IFNβ to reduce lesion sizes and re-enhancements of pre-existing CELs has not been examined extensively. Activity of contrast re-enhancing lesions (Re-CELs) and contrast single-enhancing lesions (S-CELs) were monitored in ten patients with relapsing-remitting (RR) MS. These patients underwent monthly post-contrast magnetic resonance imaging (MRIs) for an 18-month natural history phase and an 18-month therapy phase with subcutaneous IFNβ-1b, totaling 37 images per patient. The activity was analysed using the first image as a baseline and registering subsequent active monthly images to the baseline. There was a 76.4% reduction in the number of CELs with IFNβ therapy. The decrease was greater (P =0.003) for S-CELs (82.3%) than for Re-CELs (57.4%). S-CELs showed no changes in durations of enhancement and maximal lesion sizes with treatment. Exclusively for Re-CELs, IFNβ-1b significantly decreased maximal lesion sizes, total number of enhancement periods and total months of enhancement. Thus, IFNβ appears to be effective in reducing the degree of severity of inflammation among Re-CELs, as reflected by their reduced maximal lesion sizes and durations of enhancement.

Original languageEnglish (US)
Pages (from-to)658-668
Number of pages11
JournalMultiple Sclerosis
Volume11
Issue number6
DOIs
StatePublished - Dec 2005
Externally publishedYes

Fingerprint

Interferon-beta
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Natural History
Therapeutics
Magnetic Resonance Imaging
Inflammation
Interferon beta-1b

Keywords

  • Contrast-enhancing lesions
  • Interferon-beta
  • Lesion sizes
  • Magnetic resonance imaging
  • Multiple sclerosis
  • Re-enhancing lesions

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Gupta, S., Solomon, J. M., Tasciyan, T. A., Cao, M. M., Stone, R. D., Ostuni, J. L., ... Bagnato, F. (2005). Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis. Multiple Sclerosis, 11(6), 658-668. https://doi.org/10.1191/1352458505ms1229oa

Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis. / Gupta, S.; Solomon, J. M.; Tasciyan, T. A.; Cao, M. M.; Stone, R. D.; Ostuni, J. L.; Ohayon, J. M.; Muraro, P. A.; Frank, J. A.; Richert, N. D.; McFarland, H. F.; Bagnato, Francesca.

In: Multiple Sclerosis, Vol. 11, No. 6, 12.2005, p. 658-668.

Research output: Contribution to journalArticle

Gupta, S, Solomon, JM, Tasciyan, TA, Cao, MM, Stone, RD, Ostuni, JL, Ohayon, JM, Muraro, PA, Frank, JA, Richert, ND, McFarland, HF & Bagnato, F 2005, 'Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis', Multiple Sclerosis, vol. 11, no. 6, pp. 658-668. https://doi.org/10.1191/1352458505ms1229oa
Gupta, S. ; Solomon, J. M. ; Tasciyan, T. A. ; Cao, M. M. ; Stone, R. D. ; Ostuni, J. L. ; Ohayon, J. M. ; Muraro, P. A. ; Frank, J. A. ; Richert, N. D. ; McFarland, H. F. ; Bagnato, Francesca. / Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis. In: Multiple Sclerosis. 2005 ; Vol. 11, No. 6. pp. 658-668.
@article{1477e2418661437b8f7e19b1f78c00fa,
title = "Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis",
abstract = "Interferon-beta (IFNβ) reduces the number and load of new contrast-enhancing lesions (CELs) in patients with multiple sclerosis (MS). However, the ability of IFNβ to reduce lesion sizes and re-enhancements of pre-existing CELs has not been examined extensively. Activity of contrast re-enhancing lesions (Re-CELs) and contrast single-enhancing lesions (S-CELs) were monitored in ten patients with relapsing-remitting (RR) MS. These patients underwent monthly post-contrast magnetic resonance imaging (MRIs) for an 18-month natural history phase and an 18-month therapy phase with subcutaneous IFNβ-1b, totaling 37 images per patient. The activity was analysed using the first image as a baseline and registering subsequent active monthly images to the baseline. There was a 76.4{\%} reduction in the number of CELs with IFNβ therapy. The decrease was greater (P =0.003) for S-CELs (82.3{\%}) than for Re-CELs (57.4{\%}). S-CELs showed no changes in durations of enhancement and maximal lesion sizes with treatment. Exclusively for Re-CELs, IFNβ-1b significantly decreased maximal lesion sizes, total number of enhancement periods and total months of enhancement. Thus, IFNβ appears to be effective in reducing the degree of severity of inflammation among Re-CELs, as reflected by their reduced maximal lesion sizes and durations of enhancement.",
keywords = "Contrast-enhancing lesions, Interferon-beta, Lesion sizes, Magnetic resonance imaging, Multiple sclerosis, Re-enhancing lesions",
author = "S. Gupta and Solomon, {J. M.} and Tasciyan, {T. A.} and Cao, {M. M.} and Stone, {R. D.} and Ostuni, {J. L.} and Ohayon, {J. M.} and Muraro, {P. A.} and Frank, {J. A.} and Richert, {N. D.} and McFarland, {H. F.} and Francesca Bagnato",
year = "2005",
month = "12",
doi = "10.1191/1352458505ms1229oa",
language = "English (US)",
volume = "11",
pages = "658--668",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis

AU - Gupta, S.

AU - Solomon, J. M.

AU - Tasciyan, T. A.

AU - Cao, M. M.

AU - Stone, R. D.

AU - Ostuni, J. L.

AU - Ohayon, J. M.

AU - Muraro, P. A.

AU - Frank, J. A.

AU - Richert, N. D.

AU - McFarland, H. F.

AU - Bagnato, Francesca

PY - 2005/12

Y1 - 2005/12

N2 - Interferon-beta (IFNβ) reduces the number and load of new contrast-enhancing lesions (CELs) in patients with multiple sclerosis (MS). However, the ability of IFNβ to reduce lesion sizes and re-enhancements of pre-existing CELs has not been examined extensively. Activity of contrast re-enhancing lesions (Re-CELs) and contrast single-enhancing lesions (S-CELs) were monitored in ten patients with relapsing-remitting (RR) MS. These patients underwent monthly post-contrast magnetic resonance imaging (MRIs) for an 18-month natural history phase and an 18-month therapy phase with subcutaneous IFNβ-1b, totaling 37 images per patient. The activity was analysed using the first image as a baseline and registering subsequent active monthly images to the baseline. There was a 76.4% reduction in the number of CELs with IFNβ therapy. The decrease was greater (P =0.003) for S-CELs (82.3%) than for Re-CELs (57.4%). S-CELs showed no changes in durations of enhancement and maximal lesion sizes with treatment. Exclusively for Re-CELs, IFNβ-1b significantly decreased maximal lesion sizes, total number of enhancement periods and total months of enhancement. Thus, IFNβ appears to be effective in reducing the degree of severity of inflammation among Re-CELs, as reflected by their reduced maximal lesion sizes and durations of enhancement.

AB - Interferon-beta (IFNβ) reduces the number and load of new contrast-enhancing lesions (CELs) in patients with multiple sclerosis (MS). However, the ability of IFNβ to reduce lesion sizes and re-enhancements of pre-existing CELs has not been examined extensively. Activity of contrast re-enhancing lesions (Re-CELs) and contrast single-enhancing lesions (S-CELs) were monitored in ten patients with relapsing-remitting (RR) MS. These patients underwent monthly post-contrast magnetic resonance imaging (MRIs) for an 18-month natural history phase and an 18-month therapy phase with subcutaneous IFNβ-1b, totaling 37 images per patient. The activity was analysed using the first image as a baseline and registering subsequent active monthly images to the baseline. There was a 76.4% reduction in the number of CELs with IFNβ therapy. The decrease was greater (P =0.003) for S-CELs (82.3%) than for Re-CELs (57.4%). S-CELs showed no changes in durations of enhancement and maximal lesion sizes with treatment. Exclusively for Re-CELs, IFNβ-1b significantly decreased maximal lesion sizes, total number of enhancement periods and total months of enhancement. Thus, IFNβ appears to be effective in reducing the degree of severity of inflammation among Re-CELs, as reflected by their reduced maximal lesion sizes and durations of enhancement.

KW - Contrast-enhancing lesions

KW - Interferon-beta

KW - Lesion sizes

KW - Magnetic resonance imaging

KW - Multiple sclerosis

KW - Re-enhancing lesions

UR - http://www.scopus.com/inward/record.url?scp=28044453525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28044453525&partnerID=8YFLogxK

U2 - 10.1191/1352458505ms1229oa

DO - 10.1191/1352458505ms1229oa

M3 - Article

VL - 11

SP - 658

EP - 668

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 6

ER -